A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer

Trial Profile

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs AMG 757 (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 31 Oct 2017 New trial record
    • 25 Oct 2017 Planned Initiation Date has been changed from 24 Oct 2017 to 20 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top